
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group is facing some temporary headwinds due to recent changes in Medicare reimbursement, but the company's strong track record, clinical data, and market relationships make it well-positioned to outperform in the long-term. Additionally, the company's cost reduction initiatives and vertical integration in manufacturing give it a competitive advantage, and the company's international and advanced surgical segments provide stability despite the challenges in the wound care market. There is potential for significant upside in the stock as demand patterns normalize and the company sees improvements in volume and revenue.
Bears say
MiMedx Group is facing risks related to tissue donorship, competition in the "minimal manipulation" skin substitute world, and the termination or expiration of agreements with GPOs and IDNs, which could negatively impact its future business and revenue. Additionally, the company's financials may be impacted by a one-time restructuring charge and the need for efficient tissue sourcing to meet future demand. However, MiMedx has a strong portfolio of amniograft products for various healthcare applications and is supported by peer-reviewed data and evidence of economic benefit.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares